Activity of tigecycline in the treatment of acute Burkholderia pseudomallei infection in a murine model

International Journal of Antimicrobial Agents

Volumn 28, Issue 5, 2006, Pages 460-464

  Feterl, Marshall ^a   Govan, Brenda ^a   Engler, Cathy ^a   Norton, Robert ^a,b   Ketheesan, Natkunam ^a  

^a JAMES COOK UNIVERSITY   (Australia)

^b TOWNSVILLE HOSPITAL   (Australia)

Author keywords

Burkholderia pseudomallei; Therapy; Tigecycline

Indexed keywords

ANTIBIOTIC AGENT; CEFTAZIDIME; TIGECYCLINE;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; BURKHOLDERIA PSEUDOMALLEI; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; IN VIVO STUDY; MELIOIDOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; BURKHOLDERIA PSEUDOMALLEI; CEFTAZIDIME; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HUMANS; MELIOIDOSIS; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; SPLEEN; SURVIVAL RATE; VIRULENCE;

EID: 33750305322     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.07.022     Document Type: Article

References (17)

1. Dance D.A.B. Ecology of Burkholderia pseudomallei and the interactions between environmental Burkholderia spp. and human-animal hosts. Acta Trop 74 (2000) 159-168
2. Currie B.J., Fisher D.A., Howard D.M., et al. Endemic melioidosis in tropical Northern Australia: a 10-year prospective study and review of the literature. Clin Infect Dis 31 (2000) 981-986
3. Sookpranee M., Boonma P., Susaengrat W., Bhuripanyo K., and Puyagupta S. Multicenter prospective randomised trial comparing ceftazidime plus co-trimoxazole for treatment of severe melioidosis. Antimicrob Agents Chemother 36 (1992) 158-162
4. Sum P., and Petersen P. Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg Med Chem Lett 9 (1999) 1459-1462
5. Thamlikitkul V., and Trakulsomboon S. In vitro activity of tigecycline against Burkholderia pseudomallei and Burkholderia thailandensis. Antimicrob Agents Chemother 50 (2006) 1555-1557
6. Ulett G., Hirst R., Bowden B., Powell K., and Norton R. A comparison of antibiotic regimens in the treatment of acute melioidosis in a mouse model. J Antimicrob Chemother 51 (2003) 77-81
7. Ulett G., Currie B., Clair T., et al. Burkholderia pseudomallei virulence: definition, stability and association with clonality. Microbes Infect 3 (2001) 621-631
8. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Fifteenth Informational supplement. M100-515. Wayne, PA: CLSI; 2005.
9. Ulett G., Norton R., and Hirst R. Combination antimicrobial therapy of acute Burkholderia pseudomallei infection in a mouse model. Pathology 31 (1999) 264-267
10. Pankey G.A. Tigecycline. J Antimicrob Chemother 56 (2005) 470-480
11. Jounblat R., Kadioglu A., Mitchell T., and Andrew P. Pneumococcal behavior and host responses during bronchopneumonia are affected differently by the cytolytic and complement-activating activities of pneumolysin. Infect Immun 71 (2003) 1813-1819
12. Rello J. Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline. J Chemother 17 Suppl. 1 (2005) 12-22
13. Muralidharan G., Micalizzi M., Speth J., Raible D., and Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 49 (2005) 220-229
14. Conte Jr. J., Golden J., Kelly M., and Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 25 (2005) 523-529
15. Edelstein P.H., Weiss W.J., and Edelstein M.A.C. Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 47 (2003) 533-540
16. Leakey A., Ulett G., and Hirst R. BALB/c and C57I/6 mice infected with virulent Burkholderia pseudomallei provide contrasting animal models for the acute and chronic forms of human melioidosis. Microb Pathog 24 (1998) 269-275
17. Ogtrop M., Andes D., Stamstad T., et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various Gram-positive and Gram-negative bacteria. Antimicrob Agents Chemother 44 (2003) 943-949